



仁愛醫療財團法人
JEN-AI HOSPITAL

乳 癌 診 療 指 引

2009 年 06 月 03 日 制定
2010 年 05 月 11 日 一修
2011 年 05 月 25 日 二修
2012 年 05 月 30 日 三修
2013 年 04 月 24 日 四修
2014 年 04 月 09 日 五修
2015 年 04 月 08 日 六修
2016 年 04 月 06 日 七修
2017 年 04 月 05 日 八修
2018 年 04 月 11 日 九修
2018 年 09 月 19 日 十修

乳癌醫療團隊共同修訂

修訂原則


- 參與修訂科別：一般外科、腫瘤治療科、放射診斷科、乳房中心、病理科、血液暨腫瘤內科
- 診療指引需符合以下原則：
 - 一、依據實證醫學精神，並於指引中註明主要參考文獻（至少為 peer review article），若引用醫院之資料庫資料，則需提供分析及討論紀錄。
 - 二、參酌國情並經院內共識討論，且有相關會議紀錄佐證。
 - 三、定期檢視改版（至少每年一次，且明確標示制訂或修訂日期）。
 - 四、團隊共識後所訂之指引，應提送癌委會核備後公告。

DIAGNOSIS

WORK-UP

PRIMARY TREATMENT

FOLLOW-UP




DIAGNOSIS


WORK-UP

PRIMARY TREATMENT

ADJUVANT TREATMENT


FOLLOW-UP






Recurrence WORK-UP STATUS SALVAGE TREATMENT

- CBC
- Blood chemistry
- CEA and CA 15-3
- Chest x-ray
- Mammography
- Ultrasonography of breast
- Ultrasonography of liver
- Bone scan
- CT scan of chest & abdomen for locoregional recurrence(optional)
- CT scan or MRI of symptomatic areas ex.brain or spine (optional)
- Biopsy documentation of first recurrence if Possible (ER/PR Her-2)
- PET scan(optional)



Recurrence WORK-UP STATUS SALVAGE TREATMENT



備註:

1.Low risk : ER and/or PR positive and all of the following features:

grade I or II 、 PT size $\leq 2\text{cm}$ 、 K-67 $\leq 15\%$ 、 LVI(-) and age ≥ 35

2.Favorable histology: mucinous 、 tubular carcinoma

3.Consider adjuvant bisphosphonate therapy in postmenopausal patients

receiving adjuvant therapy

註一 :After surgical axillary staging

LN(-) RT to whole breast + boosting tumor bed

LN(1+~3+)RT to whole breast + boosting tumor bed

RT to supraclavicular & infraclavicular fossa

RT to internal mammary nodes

LN($\geq 4+$) RT to whole breast + boosting tumor bed

RT to supraclavicular & infraclavicular fossa

RT to internal mammary nodes

註二 :After total mastectomy

LN(-) , tumor \leq 5cm, but closed margin

RT to chest wall

LN(-) , tumor $>$ 5cm,or margin(+)

RT to chest wall, supraclavicular & infraclavicular fossa

RT to internal mammary nodes

LN(1+~3+) , tumor $>$ 5cm,or margin(+)

other prognostic factor:high grade,LN extracapsular extension,lymphovascular invasion,multicentric

RT to chest wall, supraclavicular & infraclavicular fossa

RT to internal mammary nodes


LN(\geq 4+) RT to chest wall, supraclavicular & infraclavicular fossa

RT to internal mammary nodes

註三 :A number of factors determine local recurrence risk:

palpable mass,larger size,higher grade,close or involved margins,and age $<$ 50 years.

註三 :Adjuvant hormone therapy



Radiotherapy

Treatment type	RT technique	Total dose	Fraction size / # Fractions	Note
Adjuvant RT Whole Breast Irradiation (After Breast- Conserving Surgery)	Conventionally Fractionated RT	45-50Gy to whole breast 54-60Gy to High risk local lesion boost	1.8-2Gy/ fraction	
Adjuvant RT Chest Wall and Regional Lymph Nodes Irradiation (After MRM)	Conventionally Fractionated RT	45-54Gy to ipsilateral chest wall, mastectomy scar and drain sites (ipsilateral SCF and IMC) 54-66Gy to High risk local lesion boost	1.8-2Gy/ fraction	

註：實際治療分次劑量 x 總治療次數，應與處方劑量差異在 $\pm 1\text{Gy}$ 之內。

註：放射治療詳細流程清參照 乳癌放射治療標準政策與執行規範。

Breast Cancer protocol

Neoadjuvant/Adjuvant		
Non-Trastuzumab-containing combinations		
組套名稱	組套編碼	處方內容
FEC	B-FEC-1	FEC⁷¹ Epirubicin 75-100 mg/m ² in NS 100 ml IV over 15 minutes, day 1 5-Fluorouracil 500 mg/m ² in NS 100 ml IV over 30 minutes, day 1 Cyclophosphamide 500 mg/m ² in NS 100 ml IV over 60 minutes, day 1 Cycled every 21 days
AC	B-AC	AC⁷⁵ Doxorubicin 60 mg/m ² in NS 100 ml IV over 15 minutes, day 1 Cyclophosphamide 600 mg/m ² in NS 100 ml IV over 30-60 minutes, day 1 Cycled every 21 days for 4 cycles
EC	B-EC-1	EC⁷⁶ Epirubicin 75-100 mg/m ² in NS 100 ml IV over 15 minutes, day 1 Cyclophosphamide 830 mg/m ² in NS 100 ml IV over 60 minutes, day 1 Cycled every 21 days for 8 cycles
CMF	B-CMF-2	CMF^{78.79} Methotrexate 40 mg/m ² in NS 100 ml IV over 15 minutes, days 1 5-Fluorouracil 600 mg/m ² in NS 100 ml IV over 30 minutes, days 1 Cyclophosphamide 600 mg/m ² in NS 100 ml IV over 60 minutes, day 1 Cycled every 21 days for 6 cycles

Neoadjuvant/Adjuvant		
Non-Trastuzumab-containing combinations		
組套名稱	組套編碼	處方內容
TAC	B-TAC	TAC⁷⁷ Docetaxel 75 mg/m ² in NS 250 ml IV over 60 minutes, day 1 Doxorubicin 50 mg/m ² in NS 100 ml IV over 15 minutes, day 1 Cyclophosphamide 500 mg/m ² in NS 100 ml IV over 60 minutes, day 1 Cycled every 21 days for 6 cycles
FAC	B-FAC	FAC^{73.74} Doxorubicin 50 mg/m ² in NS 100 ml IV over 15 minutes, day 1 Cyclophosphamide 500 mg/m ² in NS 100 ml IV over 60 minutes, day 1 Fluorouracil 500 mg/m ² in NS 100 ml IV over 30 minutes, days 1, 8 Cycled every 21 days for 4 cycles
TC (USOG 9735)	B-TC	TC⁶⁷ Docetaxel 75 mg/m ² in NS 250 ml IV over 60 minutes, day 1 Cyclophosphamide 600 mg/m ² in NS 100 ml IV over 60 minutes, day 1 Cycled every 21 days for 4 cycles
TP followed by FEC	B-TP	TP followed by FEC^{68.69.70} TP(Docetaxel/Cisplatin) Docetaxel 75 mg/m ² in NS 250 ml IV over 60 minutes, day 1 Cisplatin 50-60 mg/m ² in NS 300 ml IV over 120 minutes, day 1 Cycled every 21 days for 3-4 cycles followed by FEC⁷¹
	B-FEC-1	Epirubicin 75-100 mg/m ² in NS 100 ml IV over 15 minutes, day 1 5-Fluorouracil 500 mg/m ² in NS 100 ml IV over 30 minutes, day 1 Cyclophosphamide 500 mg/m ² in NS 100 ml IV over 60 minutes, day 1 Cycled every 21 days for 3-4 cycles

Neoadjuvant/Adjuvant		
Non-Trastuzumab-containing combinations		
組套名稱	組套編碼	處方內容
FEC followed by Docetaxel	B-FEC-1	FEC followed Docetaxel chemotherapy⁷¹ FEC-1 Epirubicin 75-100 mg/m ² in NS 100 ml IV over 15 minutes, days 1 5-Fluorouracil 500 mg/m ² in NS 100 ml IV over 30 minutes, days 1 Cyclophosphamide 500 mg/m ² in NS 100 ml IV over 60 minutes, day 1 Cycled every 21 days for 3-4 cycles
	B-Doce-1	Followed by Docetaxel(75-100) Docetaxel 75-100 mg/m ² in NS 250 ml IV over 60 minutes, day 1 Cycled every 21 days for 3-4 cycles
FEC followed by Paclitaxel	B-FEC-2	FEC followed by weekly Paclitaxel⁷² FEC -2 Epirubicin 90 mg/m ² in NS 100 ml IV over 15 minutes, days 1 5-Fluorouracil 600 mg/m ² in NS 100 ml IV over 30 minutes, days 1 Cyclophosphamide 600 mg/m ² in NS 100 ml IV over 60 minutes, day 1 Cycled every 21 days for 4 cycles
	B-Pacli-3	Followed by Paclitaxel(100) Paclitaxel 100 mg/m ² in NS 500 ml IV over 60 minutes, day 1 weekly for 8 weeks

Neoadjuvant/Adjuvant		
Non-Trastuzumab-containing combinations		
組套名稱	組套編碼	處方內容
AC followed by Docetaxel	B-AC	AC followed Docetaxel chemotherapy⁶⁶ AC(Doxorubicin/Cyclophosphamide) Doxorubicin 60 mg/m ² in NS 100 ml IV over 15 minutes, day 1 Cyclophosphamide 600 mg/m ² in NS 100 ml IV over 60 minutes, day 1 Cycled every 21 days for 4 cycles
	B-Doce-1	Followed by Docetaxel(75-100) Docetaxel 75-100 mg/m ² in NS 250 ml IV over 600 minutes, day 1 Cycle every 21 days for 4 cycles
AC followed by Paclitaxel	B-AC	AC followed Paclitaxel chemotherapy⁶⁶ AC(Doxorubicin/Cyclophosphamide) Doxorubicin 60 mg/m ² in NS 100 ml IV over 15 minutes, day 1 Cyclophosphamide 600 mg/m ² in NS 100 ml IV over 60 minutes, day 1 Cycled every 21 days for 4 cycles
	B-Pacli-1	Followed by Paclitaxel(80) Paclitaxel 80 mg/m ² in NS 500 ml IV over 60 minutes, weekly for 12 weeks or
	B-Pacli-2	Paclitaxel(175) Paclitaxel 175 mg/m ² in NS 500 ml IV over 180 minutes, day 1 Cycle every 21 days for 4 cycles ©AC could be modified with FEC-1

Neoadjuvant/Adjuvant		
Non-Trastuzumab-containing combinations		
組套名稱	組套編碼	處方內容
FAC followed by Paclitaxel	B-FAC	FAC followed Paclitaxel chemotherapy⁷² FAC Doxorubicin 50 mg/m ² in NS 100 ml IV over 15 minutes, day 1 5-Fluorouracil 500 mg/m ² in NS 100 ml IV over 30 minutes, days 1, 8 Cyclophosphamide 500 mg/m ² in NS 100 ml IV over 60 minutes, day 1 Cycled every 21 days for 4 cycles Followed by
	B-Pacli-3	Paclitaxel(100) Paclitaxel 100 mg/m ² in NS 500 ml IV over 180 minutes, day 1 weekly for 12 wks
Antimetabolites	B-UFUR	Uracil-Tegafur¹¹² Adjuvant: Uracil-Tegafur 200-400 mg oral daily*2 years

Neoadjuvant/Adjuvant		
Trastuzumab-containing combinations		
組套名稱	組套編碼	處方內容
AC followed by TH ± Pertuzumab	B-AC	AC followed by Paclitaxel with Trastuzumab ± Pertuzumab⁸⁰ AC(Doxorubicin/Cyclophosphamide) Doxorubicin 60 mg/m ² in NS 100ml IV over 15 minutes, day 1 Cyclophosphamide 600 mg/m ² in NS 100ml IV over 60 minutes, day 1 Cycled every 21 days for 4 cycles Followed by
	B-TH	Paclitaxel/Trastuzumab Paclitaxel 80 mg/m ² in NS 500ml IV over 1 hour , weekly for 12 wks
	B-H(6)	With Trastuzumab Trastuzumab 4 mg/kg IV with first dose of Paclitaxel,then Trastuzumab 2 mg/kg IV 90 minutes, weekly to complete 1 y of treatment. As an alternative,Trastuzumab 6 mg/kg IV every 3 wks may be used followed the completion of Paclitaxel and given to complete 1 year of Trastuzumab treatment.
	B-THPtz	Or Paclitaxel(80)/Trastuzumab/Pertuzumab⁸⁰ Paclitaxel 80 mg/m ² in NS 500ml IV over 1 hour, day 1, 8, 15 Trastuzumab 8 mg/kg IV, day 1 followed by 6 mg/kg IV Pertuzumab 840 mg IV, day 1 followed by 420 mg IV Cycles every 21 days for 4 cycles *Neoadjuvant purpose followed by surgery
	B-H(6)	Followed by Maintenance Trastuzumab Trastuzumab 6 mg/kg IV, day 1 Cycles every 21 days to complete 1y of Trastuzumab therapy Cardiac monitoring at baseline 3, 6 and 9 mo.

Neoadjuvant/Adjuvant		
Trastuzumab-containing combinations		
組套名稱	組套編碼	處方內容
AC followed by DH ± Pertuzumab	B-AC	<p>AC followed by Docetaxel with Trastuzumab⁸¹ ± Pertuzumab⁸⁰ AC(Doxorubicin/Cyclophosphamide) Doxorubicin 60 mg/m² in NS 100ml IV over 15minutes , day 1 Cyclophosphamide 600 mg/m² in NS 100ml IV over 60 minutes, day 1 Cycled every 21 days for 4 cycles Followed by Docetaxel(75-100)/Trastuzumab</p>
	B-DH	<p>Docetaxel 75-100 mg/m² in NS 250ml IV over 1 hour, day 1 Cycled every 21 days for 4 cycles With Trastuzumab Trastuzumab 8 mg/kg IV, week 1 Followed by Trastuzumab 6 mg/kg IV, every 3 weeks to complete 1 year of treatment. Or Docetaxel(75-100)/Trastuzumab/Pertuzumab⁸⁰</p>
	B-DHPtz	<p>Docetaxel 75-100 mg/m² in NS 250ml IV over 1 hour, day 1 Trastuzumab 8 mg/kg IV, day 1 followed by 6 mg/kg IV Pertuzumab 840 mg IV, day 1 followed by 420 mg IV Cycled every 21 days for 4 cycles *Neoadjuvant purpose followed by surgery Followed by Maintenance Trastuzumab</p>
	B-H(6)	<p>Trastuzumab 6 mg/kg IV, day 1 Cycles every 21 days to complete 1y of Trastuzumab therapy Cardiac monitoring at baseline 3, 6 and 9 mo. ©AC could be replaced with FEC-1</p>

Neoadjuvant/Adjuvant		
Trastuzumab-containing combinations		
組套名稱	組套編碼	處方內容
DCH ± Pertuzumab	B-DCH	<p>TCH⁸¹ followed by Trastuzumab⁸¹ ± Pertuzumab⁸² Docetaxel/Carboplatin/Trastuzumab Docetaxel 75 mg/m² in NS 250ml IV over 1 hour, day 1 Carboplatin AUC 6 in NS 250ml IV over 1 hour , days 1 Cycled every 21 days for 6 cycles With Trastuzumab Trastuzumab 4 mg/kg IV, week 1 followed by Trastuzumab 2 mg/kg IV, weekly for 17 weeks followed by 6mg/kg every 3 weeks to complete 1 y of treatment</p>
	B-DCHPtz	<p>Or Docetaxel/Carboplatin/Trastuzumab/Pertuzumab⁸² Docetaxel 75 mg/m² in NS 250ml IV over 1 hour, day 1 Carboplatin AUC 6 in NS 250ml IV over 1 hour, days 1 Trastuzumab 8 mg/kg IV, day 1 followed by 6 mg/kg IV Pertuzumab 840 mg IV, day 1 followed by 420 mg IV Cycled every 21 days for 6 cycles</p>
	B-H(6)	<p>*Neoadjuvant purpose followed by surgery Followed by Maintenance Trastuzumab Trastuzumab 6 mg/kg IV, day 1 Cycles every 21 days to complete 1y of Trastuzumab therapy Cardiac monitoring at baseline 3, 6 and 9 mo.</p>

Neoadjuvant/Adjuvant		
Trastuzumab-containing combinations		
組套名稱	組套編碼	處方內容
DCyCH followed by Trastuzumab	B-DCyCH	<p>DCyCH⁶⁹ Docetaxel/Cyclophosphamide/Trastuzumab Docetaxel 75 mg/m² in NS 250ml IV over 1 hour, day 1 Cyclophosphamide 600 mg/m² in NS 100ml IV over 1 hour, day 1 Cycled every 21 days for 4 cycles With Trastuzumab Trastuzumab 8 mg/kg IV, week 1 followed by Trastuzumab 6 mg/kg IV, Q3W x 4 cycles</p>
	B-H(6)	<p>Followed by Maintenance Trastuzumab Trastuzumab 6 mg/kg IV, day 1 Cycles every 21 days to complete 1y of Trastuzumab therapy Cardiac monitoring at baseline 3, 6 and 9 mo.</p>

Neoadjuvant/Adjuvant

Trastuzumab-containing combinations

組套名稱	組套編碼	處方內容
FEC followed by Docetaxel/ Trastuzumab/ Pertuzumab	B-FEC-3	FEC followed by Docetaxel with Trastuzumab ± Pertuzumab⁸² Epirubicin 75-100 mg/m ² in NS 100ml IV over 15 minutes, day 1 5-Fluorouracil 500 mg/m ² in NS 100ml IV over 30 minutes, day 1 Cyclophosphamide 600 mg/m ² in NS 100ml IV over 1 hour, day 1 Cycled every 21 days for 3 cycles Followed by
	B-DHPtz	Docetaxel 75-100 mg/m ² in NS 250ml IV over 60 minutes, day 1 Trastuzumab 8 mg/kg IV, day 1 followed by 6 mg/kg IV Pertuzumab 840 mg IV, day 1 followed by 420 mg IV Cycled every 21 days for 4 cycles Followed by
	B-H(6)	Maintenance Trastuzumab Trastuzumab 6 mg/kg IV ,day 1.Cycled every 21 days to complete 1 year of Trastuzumab therapy Cardiac monitoring at baseline 3, 6 and 9 mo.

Neoadjuvant/Adjuvant		
Trastuzumab-containing combinations		
組套名稱	組套編碼	處方內容
FEC followed by Paclitaxel/Trastuzumab/Pertuzumab	B-FEC-3	<p>FEC followed by Paclitaxel/Trastuzumab/Pertuzumab⁸² Epirubicin 75-100 mg/m² in NS 100ml IV over 15 minutes, day 1 5-Fluorouracil 500 mg/m² in NS 100ml IV over 30 minutes, day 1 Cyclophosphamide 600 mg/m² in NS 100ml IV over 1 hour, day 1 Cycled every 21 days for 3 cycles</p> <p>Followed by</p>
	B-THPtz	<p>Paclitaxel 80 mg/m² IV, day 1, 8, 15 Trastuzumab 8 mg/kg IV, day 1 followed by 6 mg/kg IV Pertuzumab 840 mg IV, day 1 followed by 420 mg IV Cycled every 21 days for 3 cycles</p> <p>Followed by</p>
	B-H(6)	<p>Maintenance Trastuzumab Trastuzumab 6 mg/kg IV, day 1, every 21 days to complete 1 year of Trastuzumab therapy Cardiac monitoring at baseline 3, 6 and 9 mo.</p>

Neoadjuvant/Adjuvant		
Trastuzumab-containing combinations		
組套名稱	組套編碼	處方內容
DH± pertuzumab Or TH ± pertuzumab Followed by FEC Followed by maintenance Trastuzumab	B-DH	Docetaxel with Trastuzumab (101.09)± Pertuzumab⁸³ Docetaxel(75-100)/Trastuzumab ± Pertuzumab Docetaxel 75-100 mg/m ² in NS 250ml IV over 1 hour, day 1 Trastuzumab 8 mg/kg IV, day 1 followed by Trastuzumab 6 mg/kg IV every 21 days Or
	B-DH(4)	Docetaxel 75-100 mg/m ² in NS 250ml IV over 1 hour, day 1 Trastuzumab 4 mg/kg IV, day 1 followed by Trastuzumab 2mg/kg IV weekly ±Pertuzumab 840 mg IV, day 1 followed by 420 mg IV Cycled every 21 days for 3-4 cycles or Paclitaxel(80)/Trastuzumab ± Pertuzumab Paclitaxel 80 mg/m ² in NS 500ml IV over 1 hour, day 1,8,15 Trastuzumab 8 mg/kg IV, day 1 followed by Trastuzumab 6 mg/kg IV ±Pertuzumab 840 mg IV, day 1 followed by 420 mg IV Cycled every 21 days for 3-4 cycles Followed by FEC
	B-TH	Paclitaxel 80 mg/m ² in NS 500ml IV over 1 hour, day 1,8,15 Trastuzumab 8 mg/kg IV, day 1 followed by Trastuzumab 6 mg/kg IV ±Pertuzumab 840 mg IV, day 1 followed by 420 mg IV Cycled every 21 days for 3-4 cycles Followed by FEC
	B-FEC-1	Epirubicin 75-100 mg/m ² in NS 100ml IV over 15 minutes, days 1 Fluorouracil 500 mg/m ² in NS 100ml IV ovrr 30 minutes, days 1 Cyclophosphamide 500 mg/m ² in NS 100ml IV over 60 minutes, day 1 Cycled every 21 days for 3-4 cycles Followed by Maintenance Trastuzumab
	B-H(6)	Trastuzumab 6 mg/kg IV every 21 days to complete 1 year of Trastuzumab therapy Cardiac monitoring at baseline 3, 6 and 9 mo.

Neoadjuvant/Adjuvant		
Trastuzumab-containing combinations		
組套名稱	組套編碼	處方內容
Paclitaxel/ Trastuzumab Followed by Trastuzumab	B-TH	<p>Paclitaxel/Trastuzumab⁸⁴ Paclitaxel 80 mg/m² in NS 500ml IV over 1 hour weekly for 12 weeks Trastuzumab 4 mg/kg IV with first dose of Paclitaxel followed by Trastuzumab 2 mg/kg IV weekly to complete 1 year of treatment Or Paclitaxel 175 mg/m² in NS 500ml IV over 1 hour for every 21 days Trastuzumab 8mg/kg IV with first dose of Paclitaxel followed by Trastuzumab 6 mg/kg IV for every 21 days to complete 1 year of treatment Followed by Maintenance Trastuzumab B-H(8) Trastuzumab 8 mg/kg IV day1 followed byTrastuzumab 2 mg/kg every 21 days . or B-H(6) Trastuzumab 6 mg/kg IV day1 followed byTrastuzumab 2 mg/kg every 21 days . or B-H(4)Trastuzumab 4 mg/kg IV day1 followed byTrastuzumab 2 mg/kg weekly or B-H(2)Trastuzumab 2 mg/kg IV weekly to complete 1 y of treatment.</p>
	B-H	

Metastatic/Recurrence		
Single agents		
組套名稱	組套編碼	處方內容
Anthracyclin (single agent)	B-Anthra-3	Doxorubicin(60-75)¹⁰⁶ Doxorubicin 60-75 mg/m ² in NS 100ml IV over 15 minutes, day 1 Cycled every 21 days
	B-Anthra-4	Liposomal Doxorubicin¹⁰⁷ Pegylated liposomal doxorubicin 45-50 mg/m ² in D5W 250ml IV over 2 hours, day 1 Cycled every 28 days
	B-Anthra-2	Epirubicin(60-90)¹⁰⁸ Epirubicin 60-90 mg/m ² in NS 100ml IV over 15 minutes, day 1 Cycled every 21 days
Taxanes (single agent)	B-Pacli-1	Paclitaxel(80)¹⁰⁴ Paclitaxel 80 mg/m ² in NS 500ml IV over 1 hour, day 1, weekly
	B-Pacli-2	Paclitaxel(175)¹⁰⁹ Paclitaxel 175 mg/m ² in NS 500ml IV over 3 hours, day 1 Cycled every 21 days
	B-Doce-2	Docetaxel(60-100)¹⁰³ Docetaxel 60-100 mg/m ² in NS 250ml IV over 1 hour, day 1 Cycled every 21 days
	B-Doce-3	Docetaxel(35)¹⁰⁸ Docetaxel 35 mg/m ² in NS 250ml IV over 1 hour, weekly for 6 weeks followed by a 2-week rest then repeat

Metastatic/Recurrence		
Single agents		
組套名稱	組套編碼	處方內容
Antimetabolites	B-Gem	Gemcitabine¹¹⁰ Gemcitabine 800-1200 mg/m ² IV, days 1, 8, 15 Cycled every 28 days
	B-Xel	Capecitabine¹¹¹ Capecitabine 1000-1250 mg/m ² PO twice daily, days 1-14 Cycled every 21 days
	B-UFUR	Uracil-Tegafur¹¹² Palliative: Uracil-Tegafur 200-400 mg oral daily till PD or unacceptable toxicity
Other Microtubule inhibitors	B-NAV(IV)	Vinorelbine¹¹³ Vinorelbine 25 mg/m ² in NS 50ml IV 6-10 minutes, day 1, weekly
	B-NAV(PO)	Oral Vinorelbine¹¹⁴ Vinorelbine 60 mg/m ² PO once, weekly
	B-Eribulin	Eribulin¹¹⁵ Eribulin 1.4 mg/m ² IV 2-5minutes, days 1, 8(不需稀釋, 4小時內用完) Cycled every 21 days

Metastatic/Recurrence		
Single agents		
組套名稱	組套編碼	處方內容
Other Single Agent	B-Cis	Cisplatin(75)¹¹⁶ Cisplatin 75 mg/m ² in NS 300ml IV over 2 hours, day 1 Cycle every 21 days
	B-Carbo	Carboplatin¹¹⁷ Carboplatin AUC 6 in NS 250ml IV over 60 minutes, day 1 Cycle every 21 days
	B-Everolim	Everolimus¹¹⁸ Everolimus 10 mg PO, daily Exemestane 25 mg PO, daily

Metastatic/Recurrence		
Chemotherapy combinations		
組套名稱	組套編碼	處方內容
FEC	B-FEC-4	FEC⁹⁴ Epirubicin 50 mg/m ² in NS 100ml IV over 15 minutes, days 1, 8 5-Fluorouracil 500 mg/m ² in NS 100ml IV over 30 minutes, days 1, 8 Cyclophosphamide 400 mg/m ² in NS 100ml IV over 60 minutes, day 1, 8 Cycled every 28 days
FAC	B-FAC	FAC⁹⁵ Doxorubicin 50 mg/m ² in NS 100ml IV over 15 minutes, day 1 5-Fluorouracil 500 mg/m ² in NS 100ml IV over 30 minutes, days 1, 8 Cyclophosphamide 500 mg/m ² in NS 100ml IV over 60 minutes, day 1 Cycled every 21 days
AC (Doxorubicin/ Cyclophosphamide)	B-AC	AC(Doxorubicin/Cyclophosphamide)⁹⁶ Doxorubicin 60 mg/m ² in NS 100ml IV over 15 minutes, day 1 Cyclophosphamide 600 mg/m ² in NS 100ml IV over 60 minutes, day 1 Cycled every 21 days
EC (Epirubicin/ Cyclophosphamide)	B-EC-2	EC(Epirubicin/Cyclophosphamide)⁹⁷ *For old age/heart disease Epirubicin 75 mg/m ² in NS 100ml IV over 10 minutes, day 1 Cyclophosphamide 600 mg/m ² in NS 100ml IV over 60 minutes, day 1 Cycled every 21 days

Metastatic/Recurrence		
Chemotherapy combinations		
組套名稱	組套編碼	處方內容
PLD/ Cyclophosphamide	B-PLD/Cyc	Pegylated Liposomal Doxorubicin/Cyclophosphamide⁹⁸ Cyclophosphamide 600 mg/m ² in NS 100 ml IV over 60 minutes, day 1 PLD 30 mg/m ² in D5W 250ml IV over 1 hour, day 1 Cycled every 21 days *Cyclophosphamide was administered before PLD
Docetaxel/ Capecitabine	B-Doce/Xel	Docetaxel(75)/Capecitabine⁹⁹ Docetaxel 75 mg/m ² in NS 250ml IV over 1 hour, day 1 Capecitabine 950 mg/m ² /day PO twice daily, days 1-14 Cycled every 21 days
TP (Docetaxel/Cisplatin)	B-TP	Docetaxel(75)/Cisplatin(50-60)¹⁰⁰ Docetaxel 75 mg/m ² in NS 250ml IV over 1 hour, day 1 Cisplatin 50-60 mg/m ² in NS 300ml IV over 1 hour, day 1 Cycled every 21 days for 6 cycles *For a maximum of 6 cycles or until disease progression
TAC (Docetaxel/Doxorubicin/ Cyclophosphamide)	B-TAC	TAC⁷⁷ Doxorubicin 50 mg/m ² in NS 100ml IV over 15 minutes, day 1 Docetaxel 75 mg/m ² in NS 250ml IV over 1 hour, day 1 Cyclophosphamide 500 mg/m ² in NS 100ml IV over 60 minutes, day 1 Cycled every 21 days for 6 cycles

Metastatic/Recurrence		
Chemotherapy combinations		
組套名稱	組套編碼	處方內容
GT (Gemcitabine/ Paclitaxel)	B-GT	Gemcitabine/Paclitaxel¹⁰¹ Paclitaxel 175 mg/m ² in NS 500ml IV over 3 hours, day 1 Gemcitabine 1250 mg/m ² in NS 100ml IV over 30 minutes , days 1,8 (following paclitaxel on day 1) Cycled every 21 days
GD (Gemcitabine/ Docetaxel)	B-GD	Gemcitabine/Docetaxel¹⁰² Docetaxel 75 mg/m ² in NS 250ml IV over 1 hour, day 1 Gemcitabine 1000 mg/m ² in NS 100ml IV over 30 minutes ,days 1, 8 Cycled every 21 days
GCarbo (Gemcitabine/ Carboplatin)	B-GCarbo	Gemcitabine/Carboplatin¹⁰³ Gemcitabine 1000 mg/m ² in NS 100ml IV over 30 minutes ,days 1, 8 Carboplatin AUC 2 in NS 250ml IV over 1 hour ,days 1, 8 Cycled every 21 days
CMF	B-CMF-1	CMF¹⁰⁴ Methotrexate 40 mg/m ² in NS 100ml IV over 15 minutes, days 1, 8 5-Fluorouracil 600 mg/m ² in NS 100ml IV over 30 minutes, days 1, 8 Cyclophosphamide 100 mg/m ² PO, day 1-14 Cycled every 28 days for 6 cycles

Metastatic/Recurrence		
Chemotherapy combinations		
組套名稱	組套編碼	處方內容
Paclitaxel/ Bevacizumab	B-TBev	Paclitaxel/Bevacizumab¹⁰⁵ Paclitaxel 80 mg/m ² in NS 500ml IV over 1 hour ,days 1, 8, 15 Bevacizumab 10 mg/kg in NS 100ml IV over 90 minutes ,days 1, 15 Cycled every 28 days
Palbociclib/ Fulvestrant	B-Palb/Ful	Palbociclib/Fulvestrant Palbociclib 125 mg oral ,D1-D21,Q28D Fulvestrant 500mg IM,D1,D15,D29 then Q28D Cycled every 28 days

Metastatic/Recurrence		
Preferred first-line agents for HER-2 positive disease		
組套名稱	組套編碼	處方內容
Docetaxel/ Trastuzumab ± Pertuzumab	B-DH(75-100)	Docetaxel/Trastuzumab⁸⁵ ± Pertuzumab⁸⁶ Docetaxel 75-100 mg/m ² IV, day 1, cycled every 21 days x 6-8 Trastuzumab 8 mg/kg IV, day 1 followed by 6 mg/kg IV
	B-DHPtz	±Pertuzumab 840 mg IV, day 1, then 420 mg IV Cycle every 21 days
Paclitaxel/ Trastuzumab ± Pertuzumab	B-TH(80)	Paclitaxel/Trastuzumab ± Pertuzumab⁸⁷ Paclitaxel 80 mg/m ² IV, weekly x 12 weeks
	B-THPtz(80)	Trastuzumab 4 mg/kg IV, day 1 followed by 2 mg/kg IV, weekly ±Pertuzumab 840 mg IV, day 1 followed by 420 mg IV, every 21 days
	B-TH(175)	Paclitaxel/Trastuzumab ± Pertuzumab⁸⁷ Paclitaxel 175mg/m ² IV, every 21 days x 6-8 cycles
	B-THPtz(175)	Trastuzumab 8 mg/kg IV, day 1 followed by 6 mg/kg IV, every 21 days ±Pertuzumab 840 mg IV, day 1 followed by 420 mg IV, every 21 days

Metastatic/Recurrence		
Other agents for HER-2 positive disease		
組套名稱	組套編碼	處方內容
TCH	B-TCH-1(80)	Paclitaxel(80)/Carboplatin/Trastuzumab⁸⁸ Paclitaxel 80 mg/m ² in NS 500ml IV over 1 hour, day 1, 8, 15 Carboplatin AUC 2 in NS 250ml IV over 1 hour, days 1, 8, 15 Cycled every 28 days With Trastuzumab Trastuzumab 8 mg/kg IV, day 1 followed by 6 mg/kg IV, every 21 days
	B-TCH-2(175)	Paclitaxel(175)/Carboplatin/Trastuzumab⁸⁸ Paclitaxel 175 mg/m ² in NS 500ml IV over 3 hours, day 1 Carboplatin AUC 6 in NS 250ml IV over 1 hour, day 1 Cycled every 21 days With Trastuzumab Trastuzumab 8 mg/kg IV, day 1 followed by 6 mg/kg IV, every 21 days
Vinorelbine	B-Nav(IV)	IV Vinorelbine(weekly) Vinorelbine 20 mg/m ² weekly x 4 times, then Vinorelbine 25 mg/m ² IV weekly
	B-Nav(PO)	Oral Vinorelbine Vinorelbine 60 mg/m ² , PO, days 1, 8, 15, 22 every 21 days
Vinorelbine/ Trastuzumab	B-Nav/H	Vinorelbine/Trastuzumab⁸⁹ Oral Vinorelbine 60 mg/m ² po weekly= IV Vinorelbine 25 mg/m ² IV weekly Cycled every 21 days With Trastuzumab Trastuzumab 8 mg/kg IV, day 1 followed by 6 mg/kg IV, every 21 days Or Vinorelbine 30-35 mg/m ² IV, day 1, 8 every 21 days With Trastuzumab Trastuzumab 8 mg/kg IV, day 1 followed by 6 mg/kg IV, every 21 days

Metastatic/Recurrence		
Other agents for HER-2 positive disease		
組套名稱	組套編碼	處方內容
Capecitabine/ Trastuzumab	B-Xel/H	Capecitabine/Trastuzumab⁹⁰ Capecitabine 1000-1250 mg/m ² PO twice daily, days 1-14 Trastuzumab 8 mg/kg IV, day 1 followed by 6 mg/kg IV, every 21 days Cycled every 21 days
Lapatinib/ Capecitabine	B-Lapa/Xel	Lapatinib/Capecitabine⁹¹ Lapatinib 1250 mg po daily, days 1-21 Capecitabine 1000 mg/m ² PO twice daily, days 1-14 Cycled every 21 days
Lapatinib/ Trastuzumab	B-Lapa/H	Lapatinib/Trastuzumab⁹² Lapatinib 1000 mg po daily, days 1-21 Trastuzumab 8 mg/kg IV, day 1 followed by 6 mg/kg IV, every 21 days
Ado-trastuzumab Emtansine(T-DM1)	B-TDM1	Ado-trastuzumab emtansine(T-DM1)⁹³ Ado-trastuzumab emtansine 3.6 mg/kg in NS 250ml IV over 60 minutes, day 1 Cycled every 21 days